

Broad Clinical Development Program for Cabozantinib

As of our Q2 2017 financial results call, August 2, 2017; for a full list of ongoing studies, please visit clinicaltrials.gov

Indication	Combination Regimen	Status Update
Renal Cell Carcinoma (RCC)		
First-line (intermediate- or poor-risk classification)		Preparing to file sNDA in 2017 based on results from CABOSUN† trial
First-line	+ nivolumab +/- ipilimumab	Phase 3 (CheckMate 9ER) pivotal trial initiated in July 2017, co-funded with Bristol-Myers Squibb
Hepatocellular Carcinoma		
Second-line		Phase 3 (CELESTIAL), second interim analysis expected in 2H 2017
Advanced disease	+ nivolumab +/- ipilimumab	Phase 2 (Part of CheckMate 040)
Non-Small Cell Lung Cancer		
EGFR wild-type		Phase 2†
Molecular alterations in RET, ROS1, MET, AXL, or NTRK1		Phase 2*
Genitourinary Tumors, including Bladder and Urothelial Cancers		
Genitourinary tumors	+ nivolumab +/- ipilimumab	Phase 1†
Advanced solid tumors	+ atezolizumab	Phase 1B trial initiated in June 2017, planned cohorts in RCC and urothelial carcinoma
Signal Search Opportunities to Inform Potential Development		
Pancreatic neuroendocrine and carcinoid tumors		Phase 2*
Endometrial cancer		Phase 2†
Differentiated thyroid cancer		Phase 2*
Metastatic gastrointestinal stromal tumor		Phase 2 (CABOGIST)§
Breast cancer with brain metastases	+/- trastuzumab	Phase 2*
Metastatic, hormone-receptor-positive breast cancer	+ fulvestrant	Phase 2*
Metastatic, triple negative breast cancer		Phase 2*
Soft-tissue sarcomas		Phase 2†
High-grade uterine sarcomas		Phase 2§
Relapsed osteosarcoma or Ewing sarcoma		Phase 2†
Colorectal cancer	+/- panitumumab	Phase 1*

* Trial conducted through Exelixis' Investigator-Sponsored Trial program.

† Trial conducted through collaboration with NCI's Cancer Therapy Evaluation Program.

§ Trial sponsored by the European Organisation for Research and Treatment of Cancer (EORTC).